Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of July 11, 2026, BCAX trades at $28.90 with a market cap of $1.95B and a P/E ratio of -11.39. BCAX moved -2.73% today. Year to date, BCAX is +71.78%; over the trailing twelve months it is +191.43%. Its 52-week range spans $7.80 to $30.99. Analyst consensus is strong buy with an average price target of $32.11. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for BCAX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $28.90 |
| Market Cap | $1.95B |
| P/E Ratio | -11.39 |
| EPS | $-2.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.99 |
| 52-Week Low | $7.80 |
| Volume | 490.68K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.95M |
| Gross Margin | 0.00% |
11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.11.